A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Biotech
Most Recent Events
- 01 May 2024 Status changed from not yet recruiting to recruiting.
- 27 Feb 2024 Planned initiation date changed from 31 Dec 2023 to 31 Mar 2024.
- 21 Dec 2023 New trial record